Esperion Therapeutics, Inc. (ESPR)
$0.9925
+0.00 (+0.23%)
Rating:
Recommendation:
Neutral
| Symbol | ESPR |
|---|---|
| Price | $0.9925 |
| Beta | 0.130 |
| Volume Avg. | 3.39M |
| Market Cap | 106.192M |
| Shares () | - |
| 52 Week Range | 0.85-8.87 |
| 1y Target Est | - |
| DCF Unlevered | ESPR DCF -> | |
|---|---|---|
| DCF Levered | ESPR LDCF -> | |
| ROE | 32.42% | Strong Buy |
| ROA | -117.73% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -70.74% | |
| P/E | -0.41 | Neutral |
| P/B | -0.29 | Neutral |
Latest ESPR news
About
Download (Excel)Mr. Sheldon L. Koenig
Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Global Market
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.